Combination of (a) pegylated interferon alfa-2b and (b) rebetol

Phase 3

MERCK (MRK)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Liver Transplantation

View Full Landscape

Drug Information

Target Indication

Liver Transplantation

Clinical Trial

NCT00378599

Last updated: 12/16/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA5/6/1999

Rebetol

Rebetol is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults. Rebetol is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) for paediatric patients (children 3 years of age and older and adolescents) not previously treated and without liver decompensation.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

MRK

MERCK

Healthcare•North America•NASDAQ

Related Pipeline

MK0966; Rofecoxib / Duration of Treatment: 156 weeksPhase 3

Colorectal Adenoma

CXA-201 and metronidazolePhase 3

Complicated Intra-abdominal Infection